Vaccine News and Research

Latest Vaccine News and Research

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

Media outlets interview Shah during life sciences conference in Seattle

USAID Administrator Rajiv Shah was in Seattle on Tuesday to speak at the annual Life Science Innovation Northwest conference, the Seattle Times' blog, "The Business of Giving," reports. The blog outlines the Obama administration's global health and development goals, including the six-year $63 billion Global Health Initiative (GHI), as well as some of the challenges facing Shah at USAID.

19 Mar 2010

Overall mortality rates at Bay Medical Center in Panama City drop 1.3 points

Overall mortality rates from the end of 2007 to the beginning of 2010 at Bay Medical Center in Panama City, Florida have dropped from 3.4 to 2.1. A 1.3-point drop represents a huge reduction for any hospital and translates into lives saved.

19 Mar 2010

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

19 Mar 2010

GSK's 2009 Corporate Responsibility Report published online

In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly and to making the company more responsive, more flexible and more open to the expectations of society.

19 Mar 2010

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Genocea Biosciences, a vaccine discovery and development company, today announced an exclusive worldwide license for developed countries to a portfolio of Streptococcus pneumoniae antigens from Children’s Hospital Boston. PATH and Genocea retain certain co-exclusive rights to the antigens for use in developing countries under their collaboration agreements with Children's Hospital Boston.

18 Mar 2010

New book exposes the ignored causes of three major life-threatening and chronic diseases

In his newest book, "Overlooked Causes and the Prevention: Cancer, Cardiovascular Heart Disease, Multiple Sclerosis" (published by AuthorHouse), author Arthur Douglass Alexander III exposes, delineates and documents the sometimes overlooked and often ignored causes of three major life-threatening and chronic diseases: cancer, cardiovascular disease and multiple sclerosis.

18 Mar 2010

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

Bavarian Nordic A/S announced today that it has received notification that the U.S. Food and Drug Administration (FDA) has accepted all the actions taken by the company to address the observations made during the inspection of the manufacturing facilities in 2009. This was the last step along with the clinical and preclinical data that will be used to potentially support the use of IMVAMUNE® following a declared emergency.

18 Mar 2010

iVillage launches new Health site to help women manage their health needs online

iVillage today announced the launch of its new Health site (www.ivillage.com/Health), the first women's destination on the Web that combines medical expertise and original health content with community conversations and interactive tools, to help women manage their health needs online.

18 Mar 2010

Nature News examines GAVI Alliance's budget gap

Nature News examines GAVI Alliance's multi-billion-dollar budget shortfall ahead of a donors meeting in The Hague on March 25-26.

18 Mar 2010

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

PPD and Southern Research Institute today announced they have formed a collaborative agreement in pandemic and seasonal influenza vaccine research and development to provide clients a full spectrum of influenza vaccine development services by collaborating on client bids and projects.

18 Mar 2010

Cangene receives European Commission approval to market ImmunoGam

Cangene Corporation today reports that it has received European Commission approval to market Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin), indicated for immunoprophylaxis of hepatitis B.

18 Mar 2010

Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction

Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.

17 Mar 2010

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.

17 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Simple common sense behaviors can help limit the spread of H1N1 in household: Study

Simple, common sense behaviors, including having a discussion at home about how to prevent influenza, can help limit the spread of H1N1 in a household, according to a study of the initial outbreak in New York City in 2009.

17 Mar 2010

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Healthcare personnel influenza immunization rates have remained low, despite recommendations from the Centers for Disease Control and Prevention (CDC) and other leading healthcare organizations that all healthcare personnel receive annual flu vaccines.

17 Mar 2010

Cervical cancer vaccine may protect females from post-surgical recurrence

A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham (UAB).

17 Mar 2010

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Agilent Technologies Inc. today announced the availability of new ion exchange and size exclusion columns specifically designed for the analysis of bio-molecules including monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA. The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.

17 Mar 2010

Vaccine News and Research

Latest Vaccine News and Research

Pressure BioSciences announces presentations on advantages of PCT

Media outlets interview Shah during life sciences conference in Seattle

Overall mortality rates at Bay Medical Center in Panama City drop 1.3 points

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

GSK's 2009 Corporate Responsibility Report published online

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

New book exposes the ignored causes of three major life-threatening and chronic diseases

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

iVillage launches new Health site to help women manage their health needs online

Nature News examines GAVI Alliance's budget gap

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

Cangene receives European Commission approval to market ImmunoGam

Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Simple common sense behaviors can help limit the spread of H1N1 in household: Study

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Cervical cancer vaccine may protect females from post-surgical recurrence

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in